First-line clinical outcomes of single versus compound
EGFR PACC mutations in advanced NSCLC: An
international multicentre study
43P
First-line lorlatinib versus sequential second-generation
ALK TKI followed by lorlatinib in advanced ALK-positive
non-small cell lung cancer: A real-world cohort study
48P
Becotarug (JMT101) and osimertinib (Osi) in patients (pts) with
platinum-pretreated EGFR exon 20 insertion-mutated (ex20ins)
non-small cell lung cancer (NSCLC): Final overall survival (OS)
and subgroup analyses from the BECOME phase II study
7MO
Neoadjuvant divarasib shows manageable safety and
promising activity in patients with resectable, early-stage,
KRAS G12C+ NSCLC: First results from the NAUTIKA1 KRAS
G12C+ cohort
238P
ELCC 2026
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
MUTACIONES DRIVER Y TEMPRANO